AbbVie (ABBV) Consolidated Net Income (2012 - 2026)

AbbVie (ABBV) has reported Consolidated Net Income for 15 consecutive years, with $697.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 45.93% year-over-year to $697.0 million; the TTM figure through Mar 2026 stood at $3.6 billion (down 13.37% YoY), while the FY2025 annual figure was $4.2 billion, down 1.24% from the prior year.
• Consolidated Net Income fell to $697.0 million in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Consolidated Net Income topped out at $4.5 billion in Q1 2022 and bottomed at -$97.0 million in Q1 2023.
• Historically, Consolidated Net Income has averaged $1.5 billion across 5 years, with a median of $1.4 billion in 2024.
• Annual changes were most pronounced in 2024 — Consolidated Net Income tumbled 102.79% — and 2025, when it surged 7991.3%.
• AbbVie's Consolidated Net Income stood at $2.5 billion in 2022, then slumped by 66.67% to $824.0 million in 2023, then sank by 102.79% to -$23.0 million in 2024, then soared by 7991.3% to $1.8 billion in 2025, then plunged by 61.6% to $697.0 million in 2026.
• Business Quant data shows ABBV's Consolidated Net Income at $697.0 million in Q1 2026, $1.8 billion in Q4 2025, and $188.0 million in Q3 2025.